Holen Sie sich die Stockscreener-App
167.71
0.02%
0.0505
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$167.76
Offen:
$168.59
24-Stunden-Volumen:
416.64K
Relative Volume:
0.08
Marktkapitalisierung:
$294.70B
Einnahmen:
$55.53B
Nettoeinkommen (Verlust:
$5.12B
KGV:
45.95
EPS:
3.65
Netto-Cashflow:
$15.62B
1W Leistung:
-1.08%
1M Leistung:
-10.05%
6M Leistung:
+2.98%
1J Leistung:
+20.95%
1-Tages-Spanne:
$166.92
$168.59
1-Wochen-Bereich:
$163.81
$169.63
52-Wochen-Spanne:
$137.65
$207.32
Abbvie Inc Stock (ABBV) Company Profile
Firmenname
Abbvie Inc
Sektor
Telefon
(847) 932-7900
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Vergleichen Sie ABBV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| ABBV | 167.79 | 294.70B | 55.53B | 5.12B | 15.62B | 3.65 |
| LLY | 741.91 | 693.54B | 40.86B | 8.37B | -2.28B | 5.4193 |
| NVO | 102.30 | 465.74B | 39.36B | 13.79B | 9.83B | 2.4077 |
| JNJ | 153.31 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
| MRK | 97.18 | 248.54B | 63.17B | 12.15B | 14.84B | 1.80 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-12-11 | Hochstufung | Goldman | Neutral → Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-07-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-05 | Herabstufung | Argus | Buy → Hold |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-11-08 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-08-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Underperform |
| 2022-05-06 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-02-28 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-03 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-03 | Bestätigt | Barclays | Equal Weight |
| 2022-02-03 | Bestätigt | BofA Securities | Neutral |
| 2022-02-03 | Bestätigt | Goldman | Neutral |
| 2022-01-13 | Eingeleitet | Redburn | Buy |
| 2022-01-12 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-11-23 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-23 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Hochstufung | Argus | Hold → Buy |
| 2020-05-18 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Fortgesetzt | Morgan Stanley | Overweight |
| 2020-04-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Bestätigt | Cowen | Outperform |
| 2019-09-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-20 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-04-29 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
Alle ansehen
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
LPL Financial LLC Acquires 92,492 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Sold by Trustmark National Bank Trust Department - MarketBeat
Citizens Financial Group Inc. RI Buys 4,074 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Purchases 140,368 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Sold by Intech Investment Management LLC - MarketBeat
King Luther Capital Management Corp Reduces Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Insiders Sold US$56m Of Shares Suggesting Hesitancy - Yahoo Finance
AbbVie (NYSE:ABBV) Stock Price Up 0.1% Following Analyst Upgrade - MarketBeat
Altman Advisors Inc. Boosts Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Advisors Asset Management Inc. Sells 39,044 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? - Yahoo Finance
Ontario Teachers Pension Plan Board Has $580.18 Million Stake in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Jennison Associates LLC Purchases 145,542 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Howe & Rusling Inc. Grows Stock Holdings in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Sold by Commerce Bank - MarketBeat
AbbVie Inc. stock rises Tuesday, still underperforms market - MarketWatch
AbbVie (NYSE:ABBV) Trading Down 0.7%Here's What Happened - MarketBeat
Counterweight Ventures LLC Raises Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Purchased by Avior Wealth Management LLC - MarketBeat
AbbVie (NYSE:ABBV) Price Target Raised to $195.00 at Wells Fargo & Company - MarketBeat
Where Will AbbVie Be in 5 Years? - Yahoo Finance
PNC Financial Services Group Inc. Lowers Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
B. Metzler seel. Sohn & Co. Holding AG Makes New $89.42 Million Investment in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Banque Cantonale Vaudoise Purchases 4,650 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
Beddow Capital Management Inc. Has $7.09 Million Stock Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
Fifth Third Wealth Advisors LLC Raises Stake in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.64 - Simply Wall St
AbbVie Inc. (NYSE:ABBV) Shares Bought by Meeder Asset Management Inc. - MarketBeat
Caprock Group LLC Grows Stake in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Acquired by Quest Partners LLC - MarketBeat
EC grants approval for AbbVie’s Elahere in ovarian cancer - The Pharma Letter
Thrivent Financial for Lutherans Boosts Position in AbbVie Inc. (NYSE:ABBV) - MarketBeat
What is a ‘cure,’ really? AbbVie’s Humira creator leaps into the next phase of medicine - Yahoo Finance
Regenerative Medicine Industry May See a Big Move | AbbVie, ViaCyte, Cook Biotech - openPR
AbbVie Inc. (NYSE:ABBV) Short Interest Up 12.1% in October - MarketBeat
AbbVie snaps eight straight sessions of losses - MSN
AbbVie (NYSE:ABBV) Trading Up 0.2%Time to Buy? - MarketBeat
Mawer Investment Management Ltd. Sells 14,746 Shares of AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe - Yahoo Finance
Napa Wealth Management Buys Shares of 11,771 AbbVie Inc. (NYSE:ABBV) - MarketBeat
Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products - AbbVie
Allergan Aesthetics Launches Free Business Training Platform for Healthcare Practices | ABBV Stock News - StockTitan
GLOBALT Investments LLC GA Invests $3.78 Million in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Bought by Richard C. Young & CO. LTD. - MarketBeat
Aldeyra's Dry Eye Drug Gets FDA Review, Expands $400M AbbVie Partnership Deal | ALDX Stock News - StockTitan
Aljian Capital Management LLC Invests $1.33 Million in AbbVie Inc. (NYSE:ABBV) - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Sold by MAI Capital Management - MarketBeat
AbbVie Inc. (NYSE:ABBV) Shares Sold by AMG National Trust Bank - MarketBeat
AbbVie bags EU nod for key drug from ImmunoGen takeover - pharmaphorum
AbbVie Gets European OK of Elahere in Platinum-Resistant Ovarian Cancer - MarketWatch
AbbVie’s Elahere wins European approval for certain ovarian cancers - Pharmaceutical Technology
Finanzdaten der Abbvie Inc-Aktie (ABBV)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.40%
0.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):